2024 Q2 Form 10-Q Financial Statement

#000106299324009960 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $10.08M $10.61M
YoY Change -18.39% -18.85%
Cost Of Revenue $6.157M $6.606M
YoY Change -12.13% -9.59%
Gross Profit $3.921M $4.008M
YoY Change -26.6% -30.56%
Gross Profit Margin 38.91% 37.76%
Selling, General & Admin $4.219M $3.988M
YoY Change 35.46% 12.86%
% of Gross Profit 107.58% 99.5%
Research & Development $628.8K $555.8K
YoY Change -0.66% -4.99%
% of Gross Profit 16.03% 13.87%
Depreciation & Amortization $297.3K $294.1K
YoY Change 1.67% 5.12%
% of Gross Profit 7.58% 7.34%
Operating Expenses $5.145M $4.838M
YoY Change 27.36% 9.99%
Operating Profit -$1.130M -$790.6K
YoY Change -186.06% -156.99%
Interest Expense $98.02K -$24.48K
YoY Change -681.03% 17.02%
% of Operating Profit
Other Income/Expense, Net $98.02K -$24.48K
YoY Change -680.87% 17.01%
Pretax Income -$1.032M -$815.0K
YoY Change -179.62% -159.65%
Income Tax $24.99K $1.639K
% Of Pretax Income
Net Earnings -$1.057M -$816.7K
YoY Change -236.23% -179.81%
Net Earnings / Revenue -10.49% -7.69%
Basic Earnings Per Share -$0.17 -$0.13
Diluted Earnings Per Share -$0.16 -$0.13
COMMON SHARES
Basic Shares Outstanding 6.215M shares 6.215M shares
Diluted Shares Outstanding 6.491M shares 6.504M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.33M $13.53M
YoY Change 11.11% 18.98%
Cash & Equivalents $13.33M $13.53M
Short-Term Investments
Other Short-Term Assets $3.771M $3.247M
YoY Change 12.65% -28.64%
Inventory $14.74M $17.07M
Prepaid Expenses
Receivables $5.734M $4.768M
Other Receivables $521.1K $526.4K
Total Short-Term Assets $38.09M $39.14M
YoY Change -15.07% -13.55%
LONG-TERM ASSETS
Property, Plant & Equipment $3.679M $3.744M
YoY Change 13.95% 18.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $121.7K $121.5K
YoY Change 205.32% 201.44%
Total Long-Term Assets $4.744M $4.866M
YoY Change 12.58% 15.58%
TOTAL ASSETS
Total Short-Term Assets $38.09M $39.14M
Total Long-Term Assets $4.744M $4.866M
Total Assets $42.84M $44.01M
YoY Change -12.7% -11.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.218M $3.124M
YoY Change -37.55% -13.27%
Accrued Expenses $282.6K $288.9K
YoY Change 6.21% 5.84%
Deferred Revenue
YoY Change
Short-Term Debt $400.4K $667.8K
YoY Change 37.14% 3.41%
Long-Term Debt Due $72.03K $98.19K
YoY Change -34.8% -10.28%
Total Short-Term Liabilities $3.973M $4.179M
YoY Change -44.65% -48.52%
LONG-TERM LIABILITIES
Long-Term Debt $15.60K $17.52K
YoY Change -82.22% -84.86%
Other Long-Term Liabilities $416.7K $482.5K
YoY Change -38.71% -35.29%
Total Long-Term Liabilities $432.3K $500.0K
YoY Change -43.68% -41.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.973M $4.179M
Total Long-Term Liabilities $432.3K $500.0K
Total Liabilities $4.405M $4.679M
YoY Change -45.02% -48.27%
SHAREHOLDERS EQUITY
Retained Earnings $28.93M $29.98M
YoY Change -9.03% -3.34%
Common Stock $130.6K $130.6K
YoY Change 0.19% 0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.43M $39.33M
YoY Change
Total Liabilities & Shareholders Equity $42.84M $44.01M
YoY Change -12.7% -11.07%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.057M -$816.7K
YoY Change -236.23% -179.81%
Depreciation, Depletion And Amortization $297.3K $294.1K
YoY Change 1.67% 5.12%
Cash From Operating Activities $165.6K $2.828M
YoY Change -89.24% -46.43%
INVESTING ACTIVITIES
Capital Expenditures $189.9K $49.22K
YoY Change -284.91% -86.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$189.9K -$49.22K
YoY Change -284.91% -86.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -295.5K -$495.8K
YoY Change -22.39% 21.02%
NET CHANGE
Cash From Operating Activities 165.6K $2.828M
Cash From Investing Activities -189.9K -$49.22K
Cash From Financing Activities -295.5K -$495.8K
Net Change In Cash -319.8K $2.184M
YoY Change -125.37% -48.85%
FREE CASH FLOW
Cash From Operating Activities $165.6K $2.828M
Capital Expenditures $189.9K $49.22K
Free Cash Flow -$24.30K $2.779M
YoY Change -101.48% -43.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
0 usd
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
229474 usd
CY2023Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
309947 usd
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
84200 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
84200 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-137552 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
3752 usd
CY2024Q1 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
-80473 usd
CY2023Q1 us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
0 usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
27797 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-99183 usd
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-top: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Note 1 - Basis of presentation</b></span></span></p> <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated balance sheet as of December 31, 2023 was audited and appears in the Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2024. The consolidated balance sheet as of March 31, 2024 and the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2024 and 2023, changes in stockholders' equity for the three months ended March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023, and the related information contained in these notes have been prepared by management without audit. In the opinion of management, all adjustments (which include only normal recurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles as of March 31, 2024 and for all periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. While management of the Company believes that the disclosures presented are adequate to make the information not misleading, it is suggested that these condensed consolidated financial statements be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 as filed with the Securities and Exchange Commission in the Company's Form 10-K.</span></span></p> </div>
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="margin-top: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;"><b>Note 1 - Basis of presentation</b></span></span></p> <p style="text-align: justify; margin-bottom: 0px;"><span style="font-size: 10pt;"><span style="font-family: Times New Roman,Times,serif;">The consolidated balance sheet as of December 31, 2023 was audited and appears in the Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2024. The consolidated balance sheet as of March 31, 2024 and the consolidated statements of operations and comprehensive income (loss) for the three months ended March 31, 2024 and 2023, changes in stockholders' equity for the three months ended March 31, 2024, cash flows for the three months ended March 31, 2024 and 2023, and the related information contained in these notes have been prepared by management without audit. In the opinion of management, all adjustments (which include only normal recurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles as of March 31, 2024 and for all periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. While management of the Company believes that the disclosures presented are adequate to make the information not misleading, it is suggested that these condensed consolidated financial statements be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 as filed with the Securities and Exchange Commission in the Company's Form 10-K.</span></span></p> </div>
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2064 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
681930 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
662612 usd

Files In Submission

Name View Source Status
form10q_htm.xml Edgar Link completed
0001062993-24-009960-index-headers.html Edgar Link pending
0001062993-24-009960-index.html Edgar Link pending
0001062993-24-009960.txt Edgar Link pending
0001062993-24-009960-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
leat-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
leat-20240331_cal.xml Edgar Link unprocessable
leat-20240331_def.xml Edgar Link unprocessable
leat-20240331_lab.xml Edgar Link unprocessable
leat-20240331_pre.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending